HELP Helus Pharma
Price Chart
Executive Summary
Helus Pharma announced positive topline results from a Phase 2 signal detection study of HLP004, an investigational intramuscular deuterated serotonergic agonist, for the treatment of moderate-to-severe generalized anxiety disorder (GAD). The trial showed a statistically significant and clinically meaningful 10.4-point reduction in HAM-A scores at six weeks with durable effects through six months, supporting advancement into later-stage development.
Actionable Insight
Traders should monitor upcoming regulatory interactions and potential Phase 3 trial initiation for HLP004; positive momentum may drive near-term valuation upside. Consider positioning ahead of HLP003 data in Q4 2026, which could compound investor interest.
Key Facts
- HLP004 achieved a mean reduction of 10.4 points in HAM-A scores (p<0.0001) at six weeks as adjunctive therapy in GAD patients unresponsive to standard of care.
- At six months, 67% of the pooled population were responders and 39% achieved remission.
- No drug-related serious adverse events or suicidality signals were observed; treatment effects lasted ~90 minutes with discharge readiness within ~3 hours.
- HLP004 is an investigational deuterated serotonergic agonist being developed for GAD; Helus Pharma plans to advance the program toward further development.
- The company also expects to release Phase 2 data for HLP003 in major depressive disorder in Q4 2026.
Financial Impact
Potential long-term revenue upside if HLP004 advances successfully through clinical development and gains approval, targeting a GAD market affecting over 20 million U.S. adults with no approved adjunctive therapies.
Risk Factors
- HLP004 remains investigational and has not yet entered Phase 3; clinical failure risk remains.
- Regulatory approval is uncertain despite promising Phase 2 data.
- Future financing needs could lead to equity dilution.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250048 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
8d ago
|
6-K
| $4.55 $4.30 | ▼ −5.49% | ▼ −4.77% | $3.92 (−13.85%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $5.15 $5.29 | ▲ +2.72% | ▲ +3.06% | $3.92 (−23.88%) |
|
Apr 30, 2026
5w ago
|
6-K
| $5.31 $5.15 | ▼ −3.01% | ▼ −3.23% | $3.92 (−26.18%) |
|
Apr 28, 2026
6w ago
|
6-K
| $5.16 $4.91 | ▼ −4.84% | ▼ −4.84% | $3.92 (−24.03%) |
|
Apr 20, 2026
7w ago
|
6-K
| $4.93 $5.77 | ▲ +17.04% | ▲ +16.02% | $3.92 (−20.49%) |
|
Apr 20, 2026
7w ago
|
6-K
| $4.93 $5.77 | ▲ +17.04% | ▲ +16.02% | $3.92 (−20.49%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $5.61 $4.93 | ▼ −12.12% | ▼ −11.47% | $3.92 (−30.12%) |
|
Apr 16, 2026
7w ago
|
6-K
| $5.50 $5.50 | · 0.00% | ▼ −1.21% | $3.92 (−28.73%) |
|
Apr 16, 2026
7w ago
|
Press Release
| $5.50 $5.50 | · 0.00% | ▼ −1.21% | $3.92 (−28.73%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $5.64 $5.25 | ▼ −6.91% | ▼ −5.60% | $3.92 (−30.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access